Diagnostic tools have rarely had such concerted attention as during COVID-19. And science advances have been moving modern diagnostic techniques, such as circulating tumor DNA biomarkers, epigenetic markers, DNA methylation and RNA screening, up the agenda.
But those technologies are not particularly sensitive to the early stages of cancer, said Elypta CEO Karl Bergman. The company instead has a focus on identifying cancer biomarkers based on...
Elypta was founded in 2017 by the university’s Jens Nielsen, a professor in systems biology, and his PHd student, Francesco Gatto. Nielsen, who runs what is claimed to...